肌肉减少症与非酒精性脂肪性肝病共同的发病机制

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)已成为当下最流行的肝脏疾病,是全球医疗保健的一个重大负担。肌肉减少症是指肌肉质量、强度和功能持续下降引起的综合征。骨骼肌是葡萄糖代谢的主要器官,肌肉质量下降可引起胰岛素抵抗,它是NAFLD的一个重要危险因素。此外,细胞因子、低度系统性炎症、维生素D缺乏、肠道微生态失调等可能也参与了肌肉减少症和NAFLD的病理生理机制。这篇综述主要讨论了肌肉减少症和NAFLD的共同的发病机制,它们之间的联系可能为治疗脂肪肝提供机会。

关键词: 非酒精性脂肪性肝病, 肌肉减少症, 肥胖, 胰岛素抵抗

宋叶雨, 范建高. 肌肉减少症与非酒精性脂肪性肝病共同的发病机制[J]. 肝脏, 2022, 27(4): 494-496.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21:177-186.
[2] 薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介.实用肝脏病杂志, 2020,23:457-460.
[3] Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia:an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc, 2011,12:249-256.
[4] Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens), 2018,17:321-331.
[5] 宋叶雨,范建高.少肌性肥胖合并脂肪性肝病的诊断与治疗.实用肝脏病杂志,2021,24:149-152.
[6] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab,2018,27:22-41.
[7] Deshmukh AS. Insulin-stimulated glucose uptake in healthy and insulin-resistant skeletal muscle. Horm Mol Biol Clin Investig, 2016,26:13-24.
[8] Kato K, Takeshita Y, Misu H, et al. Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig, 2015,6:158-163.
[9] Can B, Kara O, Kizilarslanoglu MC, et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res, 2017,29:745-752.
[10] Sam S, Mazzone T. Adipose tissue changes in obesity and the impact on metabolic function. Transl Res, 2014, 64:284-292.
[11] Martín AI, Priego T, López-Calderón A. Hormones and muscle atrophy. Adv Exp Med Biol, 2018,1088:207-233.
[12] Polyzos SA,Kountouras J,Zavos C,et al.The potential adverse role of leptin resistance in nonalcoholic fatty liver disease:a hypothesis based on critical review of the literature.J Clin Gastroenterol,2011,45:50-54.
[13] Jiang W,Wu N,Wang X,et al.Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.Sci Rep,2015,5:8096.
[14] Merli M,Dasarathy S.Sarcopenia in non-alcoholic fatty liver disease: targeting the real culprit?J Hepatol,2015,63:309-311.
[15] Chang WT,Wu CH,Hsu LW,et al. Serum vitamin D,intact parathyroid hormone,and Fetuin A concentrations were associated with geriatric sarcopenia and cardiac hypertrophy.Sci Rep,2017,7:40996.
[16] Yoo HJ, Hwang SY, Choi JH, et al. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One, 2017,12:e0174717.
[17] Jung TW,Chung YH,Kim HC,et al.Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle.Mol Cell Endocrinol, 2018,470:26-33.
[18] De Fré CH,De Fré MA,Kwanten WJ,et al.Sarcopenia in patients with non-alcoholic fatty liver disease:is it a clinically significant entity?Obes Rev,2019,20:353-363.
[19] Kakino S, Ohki T, Nakayama H, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res, 2018,50:80-87.
[20] Dutra MT, Avelar BP, Souza VC, et al. Relationship between sarcopenic obesity-related phenotypes and inflammatory markers in postmenopausal women.Clin Physiol Funct Imaging, 2017,37:205-210.
[21] Li CW,Yu K,Shyh-Chang N,et al.Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention.J Cachexia Sarcopenia Muscle,2019,10:586-600.
[22] Hong HC,Hwang SY,Choi HY,et al.Relationship between sarcopenia and nonalcoholic fatty liver disease:the Korean Sarcopenic Obesity Study.Hepatology,2014,59:1772-1778.
[23] Kim SH,Kwon HS,Hwang HJ.White blood cell counts,insulin resistance,vitamin D levels and sarcopenia in Korean elderly men.Scand J Clin Lab Invest,2017,77:228-233.
[24] Eliades M, Spyrou E, Agrawal N,et al. meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2013,38:246-254.
[25] Jaruvongvanich V, Ahuja W, Sanguankeo A, et al. Vitamin D and histologic severity of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis, 2017, 49:618-622.
[26] Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int, 2019,39:598-609.
[27] Ticinesi A, Nouvenne A, Cerundolo N, et al. Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia. Nutrients,2019,11:1633.